Slide 1: Results Presentation 2014 Financial Year
Vita Life Sciences Ltd Results Presentation 2014 Financial Year herbsofgold vitascience ViraLife | Enriching Lives .Since 1947 19 February 2015 5
Slide 2: Asia Pacific pharmaceutical and healthcare over-the-counter business
Asia Pacific pharmaceutical and healthcare over-the-counter business involved in the formulating, packaging, sales and distribution of vitamins and supplements 800 registered sku of vitamins and supplements sold in 8 countries in the Asia Pacific region 2 major brands 1. VitaHealth: products s
Slide 3: Disciplined management team and continued execution of proven strategy
Disciplined management team, and continued execution of VSC’s proven 1 strategy, delivers sales and profit growth while continuing expansion throughout South-East Asia 2 5th consecutive year of sales and EBIT growth culminated in EBIT of $6.9m, 24.9% growth over 2013 3 Continued strong operating cas
Slide 4: Malaysian central facility will increase operational capabilities
1 First step implemented in positioning VSC for next stage of lifecycle and growth with the appointment of CEO in Australia Malaysian central facility will increase VSC’s operational 2 capabilities: On-site new packing plant will enable VSC to increase customer service; On-site laboratory positi
Slide 5: Revenue, EBIT and DPS
Revenue EBIT DPS (A$m) (A$m) (cps) 40 8 4 30 6 3 20 4 2 10 2 1 0 0 0 2012 2013 2014 2012 2013 2014 2012 2013 2014 4
Slide 6: Revenue by geography 2012 vs 2014
2012 revenue by geography 2014 revenue by geography Other Asia Other Asia 13% 15% Australia Australia 45% 38% Singapore Asia 15% Asia Singapore 55% 15% 62% Malaysia OTC Malaysia 27% OTC 32% Total revenue: $30m Total revenue: $37m Thailand, Vietnam, Indonesia, China and Hong Kong are expected to cont
Slide 7: Australia: proven strategy delivered 22.3% EBIT growth
Management’s proven strategy delivered 22.3% EBIT growth against FY13, increasing to $3.1m Strategy remains to differentiate VSC’s unique premium ingredient formulation products within the ‘Herbs of Gold’ and ‘Vita Science’ brands and exclusively supply independent retailers The appointment in
Slide 8: Strong momentum in Vita Health
Strong momentum in ‘Vita Health’, considered one of Malaysia’s leading OTC health supplement brands, led to $11.7m in sales, a 12.9% increase over FY13 Higher EBIT margins, driven by management’s proven strategy of designing and selling unique formulation premium ingredient products, resulted in
Slide 9: Strong second half offset depressed first half sales
Strong second half offset depressed first half sales leading to consistent year on year revenue of $5.7m EBIT of $2.2m increased 12.3% against FY13 as a result of the continuation of management’s proven strategy to focus on selling unique formulation premium ingredient products Revenue (A$m) EBI
Slide 10: Sales revenue of $5.5m increased 6.1% against FY13
(1) Sales revenue of $5.5m increased 6.1% against FY13 Sales growth in Vietnam and China partially offset by a contraction in Thailand Revenue (A$m) 6 4 2 0 2013 2014 (1) Includes Malaysian MLM business) 9
Slide 11: Directors declare a final dividend of 2.0 cents per share
Directors declare a final dividend for 2014 of 2.0 cents per share. Dividends paid to shareholders in FY14 total 3.5 cents per share Final dividend will be unfranked & is fully sourced from Foreign Conduit Income Strong operating cashflow conversion combined with prudent financial management h
Slide 12: Board continues to explore strategies to capitalise on Asia-Pacific platform
The Board continues to actively explore strategies to capitalise on the established Asia-Pacific platform Two key growth strategies implemented in mature markets: Build out of ‘Vita Sciences’ brand within the Australian independent pharmacy channel Introduction of the ‘Herbs of Gold’ brand t
Slide 13: Market tailored strategies forecast to return sales growth
The implementation of market tailored strategies is forecast to return sales growth to a 3 year trendline of 8 - 10% per annum Accordingly, Directors forecast 2015 sales circa $40m with margins similiar to those achieved in 2014 12
Slide 14: Disclaimer
This document has been prepared by Vita Life Sciences Limited (Vita Life) and comprises written material/slides for a presentation concerning Vita Life. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dis
Slide 15: Contact Details
Contact Details Telephone: +61 3 9828 0500 Website: www.vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: Suite 650, 1 Queens Road, Melbourne, VIC 3004 14
Slide 16: Appendix
Appendix
Slide 17: Year ended 31 December
Year ended 31 December 2014 2013 Change $m $m % Revenue 36.58 35.41 3.3% EBITDA 7.00 5.62 24.6% EBIT 6.88 5.51 24.9% Profit before tax 6.92 5.52 25.4% Profit after tax (1) 7.28 4.75 53.3% EPS (Diluted – cents) 12.84 8.42 52.5% Dividend (cents / share) 3.50 3.00 16.7% (1) Profit After Tax includes a
Slide 18: Balance Sheet as at 31 December
Balance Sheet as at 31 December 2014 2013 $m $m Current assets 20.81 20.49 Non-current assets 9.46 1.52 Total assets 30.27 22.01 Current liabilities (5.53) (5.68) Non-current liabilities (3.17) (0.06) Total Liabilities (8.71) (5.74) Net Assets 21.56 16.27 17
Slide 19: Cash Flow
Cash Flow 2014 2013 $m $m Receipts from customers 38.97 38.86 Payments to suppliers and employees (31.95) (33.54) Gross operating cash flow 7.02 5.32 EBITDA 7.00 5.62 Gross operating cash flow / EBITDA 100.3% 94.7% Net interest received 0.12 0.07 Income tax paid (1.02) (0.56) Operating cash flows 6.